Compare Novartis AG (NVS) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Okta, Inc. — how do they compare? Novartis AG trades at $152.76 (market cap $295.37B), while Okta, Inc. trades at $150.41 (market cap $26.13B). The key difference: Novartis AG is far larger — about 11.3× Okta, Inc.'s market cap, and Novartis AG pays a 3.07% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| NVS | OKTA | |
|---|---|---|
Market Cap | $295.37B | $26.13B |
Sector | Health | Technology |
52-Week High | $168.62 | $154.62 |
52-Week Low | $119.31 | $62.93 |
Enterprise Value | $336.69B | $23.95B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
OKTA trades at $150.77, up 1.65% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $2.61B in 2025, achieving a net income of $28M after recent losses. The company maintains a 77.44% gross margin and positive operating cash flow of $750M, supported by strategic acquisitions like Permiso Security for AI threat defense.
Outlook remains positive with 72.55% analyst buy ratings and a consensus price target of $129.71, though high valuation ratios (P/E 108.93) and overbought RSI levels near 76.86 pose risks. Key catalysts include Q2 2026 earnings on August 26, 2026, and growth in cybersecurity demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
